L Yang1, Z Lv2, W Xia2, W Zhang3, Y Xin2, H Yuan2, Y Chen4, X Hu5, Y Lv6, Q Xu2, X Weng7, C Ni8,9. 1. Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou Medicine College, Hangzhou, 310014, Zhejiang, People's Republic of China. 2. Department of Breast and Thyroid Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, Zhejiang, People's Republic of China. 3. Department of Endocrinology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People's Republic of China. 4. Department of Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, Zhejiang, People's Republic of China. 5. Department of Anus and Intestine Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, Zhejiang, People's Republic of China. 6. SurExam Bio-Tech, Guangzhou Technology Innovation Base, Science City, Guangzhou, People's Republic of China. 7. Department of General Surgery, Central Hospital of Haining, Zhejiang, 310000, People's Republic of China. 8. Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, Hangzhou Medicine College, Hangzhou, 310014, Zhejiang, People's Republic of China. davenc@163.com. 9. Department of Breast and Thyroid Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, Zhejiang, People's Republic of China. davenc@163.com.
Abstract
PURPOSE: Aspirin could reduce the risk of cancer metastasis. Circulating tumor cells (CTCs) are a key factor of cancer metastasis, but no evidence has revealed how aspirin affects CTCs and its epithelial-mesenchymal transition (EMT). Here, we conducted a clinical trial to investigate how aspirin affects CTCs in metastatic colorectal cancer (MCC) and breast cancer patients (MBC). METHODS: The trial is retrospective registered at clinicaltrials.gov (NCT02602938). The eligible patients are given 100 mg aspirin q.d. for 8 weeks, and CTCs are evaluated at baseline, 4 and 8 weeks for absolute number, phenotype (epithelial type, E+, mesenchymal type, M+, and biophenotypic type, B+), and vimentin expression. RESULTS: Data on 21 MCC and 19 MBC patients are analyzed, and it revealed that the CTC numbers decreased with aspirin treatment in MCC (p < 0.001) but not MBC (p = 0.0532); besides, ratio of E+ CTCs increased (p = 0.037) and M+ CTCs decreased at 2 months in MCC (p = 0.013), but neither the ratio of E+ or M+ CTCs changes significantly in MBC; vimentin expression of M+ CTCs is higher than E+ and B+ CTCs either in MBC or MCC patients at baseline (p < 0.01); and aspirin suppresses the vimentin expression in M+ (p = 0.002)and B+ (p = 0.006) CTCs of MCC and M+ CTCs of MBC (p = 0.004); besides it find vimentin expression in B+ (p = 0.004) or M+ (p < 0.001), CTCs are markedly decreased in patients with total CTC numbers declined. CONCLUSION: Aspirin could decrease CTCs numbers and block EMT transition in MCC patients and part of MBC patients.
PURPOSE:Aspirin could reduce the risk of cancer metastasis. Circulating tumor cells (CTCs) are a key factor of cancer metastasis, but no evidence has revealed how aspirin affects CTCs and its epithelial-mesenchymal transition (EMT). Here, we conducted a clinical trial to investigate how aspirin affects CTCs in metastatic colorectal cancer (MCC) and breast cancerpatients (MBC). METHODS: The trial is retrospective registered at clinicaltrials.gov (NCT02602938). The eligible patients are given 100 mg aspirin q.d. for 8 weeks, and CTCs are evaluated at baseline, 4 and 8 weeks for absolute number, phenotype (epithelial type, E+, mesenchymal type, M+, and biophenotypic type, B+), and vimentin expression. RESULTS: Data on 21 MCC and 19 MBCpatients are analyzed, and it revealed that the CTC numbers decreased with aspirin treatment in MCC (p < 0.001) but not MBC (p = 0.0532); besides, ratio of E+ CTCs increased (p = 0.037) and M+ CTCs decreased at 2 months in MCC (p = 0.013), but neither the ratio of E+ or M+ CTCs changes significantly in MBC; vimentin expression of M+ CTCs is higher than E+ and B+ CTCs either in MBC or MCC patients at baseline (p < 0.01); and aspirin suppresses the vimentin expression in M+ (p = 0.002)and B+ (p = 0.006) CTCs of MCC and M+ CTCs of MBC (p = 0.004); besides it find vimentin expression in B+ (p = 0.004) or M+ (p < 0.001), CTCs are markedly decreased in patients with total CTC numbers declined. CONCLUSION:Aspirin could decrease CTCs numbers and block EMT transition in MCC patients and part of MBCpatients.
Authors: Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron Journal: J Natl Cancer Inst Date: 2009-02-10 Impact factor: 13.506
Authors: Ryan P Roop; Michael J Naughton; Catherine Van Poznak; Jochen G Schneider; Philip E Lammers; Timothy J Pluard; Farley Johnson; Charles S Eby; Katherine N Weilbaecher Journal: Clin Breast Cancer Date: 2013-12 Impact factor: 3.225
Authors: C R Lindsay; S Le Moulec; F Billiot; Y Loriot; M Ngo-Camus; P Vielh; K Fizazi; C Massard; F Farace Journal: BMC Cancer Date: 2016-02-29 Impact factor: 4.430
Authors: Angelo Restivo; Ivana Maria Francesca Cocco; Giuseppe Casula; Francesco Scintu; Francesco Cabras; Mario Scartozzi; Luigi Zorcolo Journal: Br J Cancer Date: 2015-09-15 Impact factor: 7.640
Authors: Preeti Kanikarla-Marie; Michael Lam; Alexey V Sorokin; Michael J Overman; Scott Kopetz; David G Menter Journal: Front Oncol Date: 2018-04-20 Impact factor: 6.244
Authors: Ana Carolina Ruberte; Gustavo González-Gaitano; Arun K Sharma; Carlos Aydillo; Ignacio Encío; Carmen Sanmartín; Daniel Plano Journal: Int J Mol Sci Date: 2020-11-27 Impact factor: 5.923